Synonyms: TL 32711 | TL-32711 | TL32711
Compound class:
Synthetic organic
Comment: Birinapant is an experimental anti-cancer compound.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Birinapant is being assessed in clinical trials to test effectiveness in patients with various types of cancer, either alone or in combination with other chemotherapeutic drugs. ClinicalTrials.com lists all currently registered trials using this compound. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Birinapant is a small molecule peptidomimetic of SMAC (second mitochondrial-derived activator of caspases) that selectively targets IAPs (inhibitors of apoptosis) and inhibits their activity. The compound effectively turns off NF-κB pro-survival signalling and synergises with pro-apoptotic ligands (eg TNFα and TRAIL) to direct cells towards the caspase-dependent pro-apoptotic pathway [1-4]. Birinapant exhibits somewhat selective binding activity for cellular inhibitor of apoptosis 1 (cIAP1) compared to cIAP2. Birinapant also antagonizes the function of XIAP (X-linked inhibitor of apoptosis) which permits activation of the caspases which terminate the extrinsic and intrinsic apoptosis pathways. |